Overview

The 148-gene solid tumor NGS panel is a comprehensive genomic profiling assay designed to interrogate one hundred and forty-eight cancer-related genes from a single tissue specimen. The panel is built around the categories of gene alterations that drive solid tumor biology: oncogenic drivers, tumour suppressor genes, DNA repair genes, and predictive biomarkers for targeted therapy and immunotherapy. The advertised eight-working-day turnaround is intended to fit within the typical clinical decision window for advanced disease.

A comprehensive panel is not for every patient. The decision to order a 148-gene panel rather than a smaller targeted panel is informed by the disease stage, the availability of tissue, and the treatment options that the result could open. From a population perspective, certain groups benefit more clearly than others.

Populations That Benefit Most

Patients with advanced or metastatic solid tumors who have exhausted standard-of-care options are the clearest candidates for comprehensive profiling. Per NCCN, broad molecular profiling is recommended for many advanced solid tumors because targeted therapies matched to specific alterations can change the treatment course. A 148-gene panel has a higher likelihood than a smaller panel of finding an actionable alteration, particularly in rare tumour types where the driver landscape is less well defined.

Patients with rare cancers also benefit. Rare tumour types such as cholangiocarcinoma, salivary gland cancers and certain sarcomas often have driver alterations that a focused panel would miss. The comprehensive panel captures these low-frequency but clinically actionable events in a single test, sparing the patient and clinician from sequential single-gene workups.

Patients with strong family histories suggestive of a hereditary cancer syndrome may benefit, although germline confirmation requires a dedicated germline assay. The 148-gene panel can flag suspected germline findings that warrant separate confirmation in a CLIA-certified germline laboratory.

Populations Where a Smaller Panel May Suffice

Patients with a single, well-characterised driver alteration already identified on a smaller panel do not need a comprehensive panel unless progression is observed. For these patients, reflex testing at progression is the more efficient strategy. Similarly, patients with limited life expectancy and no access to clinical trials may not benefit from additional molecular findings that cannot be acted upon.

The eight-working-day turnaround favours patients whose clinical decision window aligns with the assay timeline. Urgent cases may require a rapid single-gene or small-panel test to support the immediate decision, with comprehensive profiling added once the acute decision is settled.

Logistics and Tissue Stewardship

A 148-gene panel consumes more tissue than a small panel. Pathologists should plan the block allocation accordingly, particularly for core biopsies where tissue is limited. Per best practice, an H&E review precedes nucleic acid extraction to confirm tumour cellularity, and macrodissection is used where appropriate to enrich the tumour fraction.

FAQ

Q: Is comprehensive profiling appropriate for early-stage solid tumors? A: NCCN recommendations focus on advanced disease. Early-stage patients are profiled selectively where the result would change adjuvant therapy decisions.

Q: How does an eight-working-day turnaround affect clinical decisions? A: It supports most outpatient decision windows for advanced disease. Emergency decisions require faster assays.

Q: What happens if a 148-gene panel finds a suspected germline alteration? A: The result is confirmed in a CLIA-certified germline laboratory before clinical action is taken, per ACMG and NCCN guidance.

Q: Does the panel report immunotherapy biomarkers? A: Yes. Tumour mutational burden and other immunotherapy-relevant markers are reported where the panel design supports them.